Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.19 ^USD	+4.39%		+5.31%	+35.23%

06-28	Atossa Therapeutics Doubles Z-Endoxifen Dose in Phase 2 Breast Cancer Study	MT
06-28	Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	CI

Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.

April 01, 2024 at 04:06 pm

From October 1, 2023 to December 31, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,320,046 shares, representing 1.04% for $1.44 million under the buyback announced on June 27, 2023.

Latest news about Atossa Therapeutics, Inc.

Atossa Therapeutics Doubles Z-Endoxifen Dose in Phase 2 Breast Cancer Study	06-28	MT
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	06-28	CI
Atossa Therapeutics Set to Join Updated Russell 3000 Index	06-17	MT
Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model	05-28	CI
Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	05-15	MT
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	05-15	CI
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering	05-13	MT
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.	05-13	CI
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force	05-07	CI
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	04-29	CI
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	04-15	CI
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	04-09	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.	04-01	CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	03-19	CI
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors	03-12	CI
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	02-22	CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating	02-12	MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4	02-12	MT
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial	02-07	CI
Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million.	12-30	CI
Atossa Therapeutics, Inc's Equity Buyback Plan Extended till December 31, 2024.	12-17	CI
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director	12-04	CI

Chart Atossa Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.19 USD

Average target price

5.417 USD

Spread / Average Target

+355.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATOSSA THERAPEUTICS, INC.	+35.23%	143M
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-8.62%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	31.24B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.06B
MEDPACE HOLDINGS, INC.	+34.36%	13.12B
BIO-TECHNE CORPORATION	-7.14%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.68B

Other Biotechnology & Medical Research